Clorox CO /DE/ 8-K filings

The Clorox Company announced its fourth quarter and full fiscal year 2026 results, reporting a 2% net sales decrease for Q4 and a 5% decrease for the full year, impacted by ERP transition effects and acquisition costs, while providing a FY27 outlook with expected organic sales growth.

The Clorox Company announces a simplified operating structure and key executive appointments to enhance execution and accelerate growth.

The Clorox Company announced that Chair and CEO Linda Rendle will step down following the appointment of a successor to focus on her health.

The Clorox Company has successfully closed a public offering of $1.55 billion in senior notes across three tranches maturing in 2031, 2033, and 2036.

The Clorox Company has completed its acquisition of GOJO Industries, integrating the Purell brand and expanding its health and hygiene offerings.

Clorox reported a 1% net sales decrease and a 16% diluted EPS drop for Q2 FY2026, while reaffirming its full-year outlook.

Clorox expands its health and hygiene portfolio by acquiring GOJO Industries, makers of PURELL, for $2.25 billion in cash, including tax benefits.

The Clorox Company's annual shareholder meeting saw the election of all director nominees, advisory approval of executive compensation, and ratification of Ernst & Young LLP as auditor.

The Clorox Company reported a significant decline in first-quarter fiscal year 2026 sales and earnings, primarily attributed to the expected impact of its enterprise resource planning (ERP) system transition.

The Clorox Company announced the resignation of Eric Reynolds, Executive Vice President, Chief Operating and Strategy Officer, after 27 years of service.

The Clorox Company delivered robust margin expansion and adjusted EPS growth for fiscal year 2025, despite missing second-half topline expectations, and anticipates a significant sales and earnings decline in fiscal year 2026 due to the reversal of retailer inventory build-up ahead of its U.S. ERP system implementation.

The Clorox Company has amended and restated its bylaws, effective May 19, 2025, introducing a cure process for deficiencies in director nomination notices and designating Delaware as the exclusive forum for certain legal proceedings.

Gina Boswell, CEO of Bath & Body Works, has been elected to Clorox's Board of Directors, effective May 19, 2025.

Clorox reported lower-than-expected sales for Q3 2025 due to a challenging consumer and geopolitical landscape, but maintained market share and achieved its tenth consecutive quarter of gross margin expansion.

The Clorox Company entered into a new $1.2 billion five-year unsecured revolving credit agreement, replacing its existing credit agreement.

Clorox reported a decrease in net sales but an increase in diluted EPS for Q2 fiscal year 2025, and updated its full-year outlook, including the wind down of the Glad bags and wraps joint venture with P&G.

Clorox's Chief Financial Officer, Kevin Jacobsen, will retire effective April 1, 2025, and will be succeeded by Luc Bellet, currently the company's Treasurer.

Clorox shareholders elected all director nominees, approved executive compensation, and ratified the selection of Ernst & Young as the independent auditor at the annual meeting on November 20, 2024.

Clorox's first quarter of fiscal year 2025 saw a significant rebound in sales and profitability, driven by lapping the prior year's cyberattack and strong operational performance, leading to an increased full-year outlook.

Clorox has completed the divestiture of its Better Health Vitamins, Minerals and Supplements business to an affiliate of Piping Rock Health Products, LLC.

Clorox reported its fourth quarter and fiscal year 2024 results, including a 6% net sales decrease for the quarter, and announced the sale of its Better Health Vitamins, Minerals and Supplements business.

Clorox reported a 5% decrease in net sales for Q3, but showed progress in recovering from a cyberattack and made strategic moves including the divestiture of its Argentina business.

Clorox has divested its operations in Argentina, Uruguay, and Paraguay to Apex Capital, a private equity fund, as part of its IGNITE strategy to focus on core business growth.

Clorox reported a strong second quarter with significant sales growth and margin expansion, driven by recovery from a cyberattack and effective cost management, leading to an improved full-year outlook.